Coffea arabica 6c homeopathic tablets
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 8 · 1995–2025
Showing the 50 most relevant studies, sorted by most relevant.
Selena Ahmed, Sarah Brinkley, Erin Smith, et al.
Frontiers in Plant Science, 2021
Athina Koutouleas, Thuan Sarzynski, B. Bertrand, et al.
Agronomy for Sustainable Development, 2022
Vivek Dhand, Vivek Dhand, L. Soumya, et al.
Materials science & engineering. C, Materials for biological applications, 2016
Lorenzo Rossi, Lauren Fedenia, H. Sharifan, et al.
Plant physiology and biochemistry : PPB, 2019
W. P. Rodrigues, M. Q. Martins, A. Fortunato, et al.
Global Change Biology, 2016
Cleide Nascimento Campos, R. G. Ávila, K. R. D. de Souza, et al.
Agricultural Water Management, 2019
A. Duangjai, Nungruthai Suphrom, Jukkrit Wungrath, et al.
Integrative Medicine Research, 2016
Grațiana Ruse, Alex-Robert Jîjie, Elena-Alina Moacă, et al.
Pharmaceuticals, 2025
Background: Coffea arabica, commonly known as Arabica coffee, has garnered attention in recent years for its potential applications in dermato-cosmetic formulations. This review aims to critically evaluate the emerging role of Coffea arabica as an active ingredient in skin care products, focusing on its bioactive compounds derived from both the leaves and beans, mechanisms of action, and efficacy in dermatological applications. A comparative analysis between the bioactive profiles of the leaves and beans is also presented to elucidate their respective contributions to dermato-cosmetic efficacy. Results: This review synthesizes findings from various studies that highlight the presence of key bioactive compounds in Coffea arabica, including caffeine, chlorogenic acids, and flavonoids. Notably, the leaves exhibit a higher concentration of certain phenolic compounds compared to the beans, suggesting unique properties that may enhance skin health. These compounds have demonstrated significant anticellulite, anti-inflammatory, antioxidant, photoprotective, anti-aging, antibacterial, and moisturizing properties. Discussion: This article delves into the biochemical pathways through which bioactive compounds derived from both the leaves and beans of Coffea arabica exert their beneficial effects on skin and hair health. Furthermore, this review highlights the growing trend of incorporating natural ingredients in cosmetic formulations and the consumer demand for products with scientifically substantiated benefits. Conclusions: The findings of this review underscore the potential of Coffea arabica as a valuable active ingredient in dermato-cosmetic applications. Its multifaceted bioactivity suggests that it can contribute significantly to skin health and cosmetic efficacy. Future research should focus on clinical trials to further validate these benefits and explore optimal formulation strategies for enhanced delivery and stability in cosmetic products.
Abstract licence: CC BY
Yebirzaf Yeshiwas Melese, S. Kolech
Sustainability, 2021
E Kemsley
Food Chemistry, 1995
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.